Bico Group - Biotech's future

Mattek and Visikol sold for $80M at 4x sales price.

I can’t be bothered to look up what was paid for these now, but it sounds good.

This company’s journey from the COVID bubble to here has certainly been quite a mess. Acquired all sorts of things suitable for the CEO’s visions at exorbitant valuations (fortunately, partly using its own overpriced shares) - then hit a wall as interest rates rose, and now divesting the same acquisitions.

2 Likes

Bico Group Audiocast Q3’25:

2 Likes